ArticleThoracic cancer2026

PACIFIC-5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC.

Shiqiong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.